Terminated PHASE3 INTERVENTIONAL 1-arm NCT03245840

Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Participants With Eosinophilic Esophagitis (EoE)

A Phase 3, Multicenter, Open-label Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE)

Sponsor: Shire

Conditions Eosinophilic Esophagitis (EoE)

Interventions Budesonide oral suspension

Updated 18 times since 2017 Last updated: Jan 30, 2025 Started: Oct 5, 2017 Primary completion: Apr 26, 2022 Completion: Apr 26, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor decision

Other terminated trials from Shire

See all terminations from Shire

Listed as NCT03245840, this PHASE3 trial focuses on Eosinophilic Esophagitis (EoE) and remains terminated or withdrawn. Sponsored by Shire, it has been updated 18 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

18 versions recorded

Mar 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Mar 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Jan 2023 — Jul 2024 [monthly]

Terminated PHASE3
Jun 2022 — Jan 2023 [monthly]

Terminated PHASE3

Status: Active Not Recruiting → Terminated

▶ Show 13 earlier versions

Nov 2021 — Jun 2022 [monthly]

Active Not Recruiting PHASE3
Sep 2021 — Nov 2021 [monthly]

Active Not Recruiting PHASE3
Jan 2021 — Sep 2021 [monthly]

Active Not Recruiting PHASE3
Oct 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE3
Jun 2020 — Oct 2020 [monthly]

Active Not Recruiting PHASE3
Feb 2020 — Jun 2020 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Nov 2019 — Feb 2020 [monthly]

Recruiting PHASE3
Apr 2019 — Nov 2019 [monthly]

Recruiting PHASE3
Jun 2018 — Apr 2019 [monthly]

Recruiting PHASE3
Feb 2018 — Jun 2018 [monthly]

Recruiting PHASE3
Dec 2017 — Feb 2018 [monthly]

Recruiting PHASE3
Oct 2017 — Dec 2017 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Aug 2017 — Oct 2017 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shire
Takeda Development Center Americas, Inc.

Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Astoria, United States , Atlanta, United States , Aurora, United States , Baton Rouge, United States , Birmingham, United States , Boston, United States , Bristol, United States , Chapel Hill, United States , Charlotte, United States , Chestnut Hill, United States and 32 more locations